- PharmAla Biotech Holdings (MDMA) received purchase order from Incannex (IHL) for GMP LaNeo MDMA and Psilocybin
- PharmAla will be the initial supplier for clinical materials in a series of Psychedelic therapy clinics planned for opening by Incannex in Melbourne and across Australia
- Incannex is developing unique pharmaceutical products and psychedelic medicine therapies
- PharmAla Biotech Holdings (MDMA) is trading at $0.39
PharmAla Biotech Holdings (MDMA) received a purchase order from Incannex (IHL) for GMP LaNeo MDMA and Psilocybin.
PharmAla will be the initial supplier for clinical materials in a series of Psychedelic therapy clinics planned for opening by Incannex in Melbourne and across Australia.
“A significant number of companies have come to a similar conclusion: only PharmAla Biotech can be trusted to ensure a safe, predictable and regulatory-compliant drug supply for patients in the nascent Australian medical Psychedelics market,” said Nick Kadysh, PharmAla’s CEO.
Clinical stage pharmaceutical development firm Incannex is psychedelic research company and clinic operator based in Australia. It is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleepapnea, traumatic brain injury and concussion, lung inflammation, rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications.
The first publicly-traded company to manufacture GMP MDMA, PharmAla Biotech is a biotechnology company focused on researching, developing, and manufacturing MDXX-class molecules, including MDMA.
PharmAla Biotech Holdings (MDMA) is trading at $0.39.
For full disclaimer information, please click here.
